Remove Construction Remove Court Remove Court Decisions Remove Prima Facie Case
article thumbnail

Obviousness and Pharmaceutical Method of Treatment Claims

Patently O

by Dennis Crouch In April 2024, the Federal Circuit issued a significant decision vacating a district court’s judgment that Janssen Pharmaceuticals’ dosing regimen patent claims were nonobvious. The case involved Janson’s U.S. Overall, this is a bad case for pharmaceutical formulary patents. Teva Pharms.